Precision Gene Editing & "Armored" CAR Platforms

Online Inquiry

Background Service Service Packages Our Core Technologies Highlights FAQs Contact

Despite the clinical success of CAR-T therapies, challenges remain, including limited persistence, antigen escape, tumor microenvironmental immunosuppression, and off-target genotoxicity. Our Precision Gene Editing & "Armored" CAR Platforms integrate next-generation CRISPR-derived tools with constitutively active cytokine or checkpoint-modulatory cassettes to engineer multi-functional cell products. We offer fully customizable, end-to-end services, from target design and vector construction to in vivo efficacy modeling tailored for both autologous and allogeneic settings. Our solutions ensure high editing fidelity, enhanced intratumoral fitness, and reduced manufacturing variability, empowering you to accelerate translational timelines and achieve robust, durable responses in refractory malignancies.

Introduction

Precision gene editing, empowered by programmable nucleases such as CRISPR-Cas9 and its advanced derivatives including base editors and epigenetic modulators, has revolutionized cell therapy engineering by enabling site-specific genomic modifications with unprecedented accuracy, thereby allowing for the functional knockout of inhibitory checkpoints, the knock-in of therapeutic transgenes, and the fine-tuning of cellular metabolism to enhance antitumor potency. Meanwhile, the "armored" CAR platform represents a paradigm shift in overcoming the immunosuppressive tumor microenvironment, wherein engineered cells are equipped with inducible cytokine payloads or synthetic receptor circuits that not only provide intrinsic survival and proliferative signals but also actively remodel the local immune landscape, recruit endogenous effectors, and sustain long-term therapeutic activity against otherwise resistant solid tumors.

Fig.1 Methods for leveraging cytokine-mediated signal transduction. (OA Literature) Fig.1 Strategies for utilizing cytokine signaling networks. ¹

Our Service

Our Precision Gene Editing & "Armored" CAR Platforms synergize next-generation CRISPR tools with constitutive cytokine or checkpoint-modulatory cassettes to engineer multifunctional cell therapies. We address key barriers persistence, antigen escape, and immunosuppression, while ensuring high editing fidelity and reduced variability. We provide fully customizable, end-to-end solutions, from design to in vivo modeling, accelerating durable responses in refractory malignancies.

Service Packages

CRISPR-Enabled Universal CAR-T (UCAR-T) Development Platform

Our platform enables the generation of off-the-shelf, allogeneic CAR-T products by leveraging multiplex CRISPR editing to disrupt endogenous TCR and HLA expression, thereby mitigating graft-versus-host disease and allorejection. It supports large-scale, standardized manufacturing from healthy donor sources, significantly reducing production lead times and costs. This approach is particularly suited for acute clinical scenarios requiring rapid intervention, and allows for repeated dosing schedules without the leukapheresis burden on heavily pre-treated patients.

Learn More →

Site-Specific CAR Knock-In & Genomic "Safe Harbor" Integration Platforms

Our solution ensures precise, non-disruptive transgene insertion into validated genomic safe harbors (e.g., AAVS1, TRAC locus) using next-generation CRISPR tools and homology-directed repair or non-homologous end-joining strategies. By avoiding random viral integration, it guarantees predictable and sustained CAR expression, minimizes oncogenic insertion risks, and maintains native cellular physiology. This platform is critical for developing safer, more stable cell products with consistent potency, especially for indications requiring long-term disease control and iterative genetic engineering.

Learn More →

LNP-Mediated CRISPR/Cas9 Gene Editing Platform

This non-viral platform leverages lipid nanoparticle (LNP) formulations to deliver CRISPR/Cas9 ribonucleoproteins (RNPs) or mRNA/gRNA complexes directly into primary T cells, enabling efficient, transient gene knockout with minimal off-target activity and reduced immunogenicity compared to viral vectors. The LNP approach supports high-throughput, scalable transfection with excellent cell viability, and is readily adaptable for multiplexed editing.

Learn More →

LNP-Based Base Editing Platform for Precision CAR-T

This platform harnesses LNP-delivered base editors to introduce precise single-nucleotide conversions in T-cell genomes without inducing double-strand breaks, enabling highly accurate gene silencing or activation of specific signaling checkpoints to create "armored" CAR-T cells resistant to immunosuppressive microenvironments. It offers superior precision and safety over conventional CRISPR knockouts, preserving genomic integrity while fine-tuning T cell fitness and persistence.

Learn More →

Our Core Technologies

We offer comprehensive precision gene editing platforms, encompassing CRISPR-Cas9 HDR, base editing, and epigenetic modulation, integrated with multidimensional armored CAR engineering to deliver next-generation cell therapies with enhanced safety, persistence, and tumor microenvironment control.

Our Core Technologies of precision gene editing & armored CAR platforms at Creative Biolabs. (Creative Biolabs Original)

Key Advantages

Superior Editing Fidelity & Safety: Our next-generation CRISPR-derived tools enable highly precise, site-specific transgene integration into validated genomic safe harbors, minimizing off-target genotoxicity and random insertion risks—critical for regulatory approval and patient safety.
Multifunctional "Armored" Design: By incorporating constitutively active cytokine or checkpoint-modulatory cassettes, our CAR products actively resist the immunosuppressive tumor microenvironment, enhance intratumoral persistence, and prevent antigen escape, driving robust and durable antitumor activity.
Versatile & Customizable End-to-End Solutions: We offer fully tailored services from target design and vector construction to in vivo efficacy modeling, supporting both autologous and allogeneic settings, ensuring seamless transition from discovery to clinical translation.

FAQ

Q1: What types of gene editing tools do you use, and how do you ensure specificity?

A1: We employ next-generation CRISPR-derived systems combined with optimized guide RNA design and bioinformatic off-target prediction. Every editing event is validated by deep sequencing and unbiased genome-wide translocation analysis to guarantee exceptional on-target precision and minimal genotoxicity.

Q2: What does "Armored" mean in your CAR platform?

A2: "Armored" refers to the incorporation of constitutively active cytokine signaling or checkpoint-modulatory cassettes into the CAR construct. This engineering enhances T cell persistence, resistance to tumor microenvironmental suppression, and sustained effector function, even in hostile solid tumors.

Why Choose Us?

Our integrated platform uniquely combines state-of-the-art precision gene editing, spanning CRISPR-Cas9 HDR, base editing, and epigenetic modulation, with rationally designed armored CAR strategies. We deliver tailored solutions that precisely control transgene expression, overcome immunosuppressive microenvironments, and enhance in vivo persistence, accelerating the development of safer, more efficacious next-generation cell therapies for solid and hematological malignancies.

How to contact us?

Looking to propel your immunotherapy program forward? Our seasoned scientists are ready to assess your unique challenges—whether you're at the target identification stage or preparing for studies. We bring flexible partnership options, tailored development roadmaps, and aggressive timelines for early proof-of-concept data. Connect with us to see how our gene-editing and armored CAR solutions can give your pipeline a competitive edge. We're eager to collaborate on your next breakthrough.

Reference

Yang, Dorothy D et al. "Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment." Frontiers in immunology vol. 16 1643941. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2025.1643941.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.